Cindy Keys

Pharmacosmos Therapeutics Inc.

Pharmacosmos Therapeutics Inc., the US affiliate of Pharmacosmos, has been established to pursue FDA approval of and ultimately commercialize Pharmacosmos products in the US market. The company is creating a collaborative, performance-based culture in which employees are recognized and rewarded for the value they bring to the organization and empowered to do meaningful work. Pharmacosmos Therapeutics Inc. is located in Morristown, NJ. Pharmacosmos, an international company headquartered in Denmark, is considered a world leading authority in treatment of iron deficiency anemia. Pharmacosmos is family-owned with more than 50 years of innovation and leadership in iron- and carbohydrate-based treatments for human and animal use. A research-based company, its ongoing R&D program focuses on improving the lives of patients with iron deficiency anemia. In the 2016 Global Burden of Disease study1, Iron Deficiency Anemia was ranked as one of the ten most prevalent global conditions with an estimated 1.24 billion conditions reported.1. Pharmacosmos has affiliates in the US, UK, Ireland, Germany, Sweden and Norway and its products are marketed in more than 80 countries across the world. Its manufacturing facilities are approved, among others, by the Danish Medicines Agency. For more information about Pharmacosmos, visit www.pharmacosmos.com. 1.Global Burden of Disease (GBD) 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990 – 2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390 (10100): p. 1211 – 1259. 2019-68 v.1